Gut microbial composition in patients with psoriasis

Francisco M. Codoñer¹, Ana Ramírez-Bosca²,³, Eric Climent¹, Miguel Carrión-Gutierrez⁴, Mariano Guerrero⁵, Jose Manuel Pérez-Orquín⁶, José Horga de la Parte⁶, Salvador Genovés⁷, Daniel Ramón¹,⁷, Vicente Navarro-López⁵,⁸ & Empar Chenoll³

Since the last 5–10 years the relevance of the gut microbiome on different intestinal illnesses has been revealed. Recent findings indicate the effect of gut microbiome on certain dermatological diseases such as atopic dermatitis. However, data on other skin diseases such as psoriasis are limited. This is the first time attempting to reveal the gut microbiome composition of psoriatic patients with a prospective study including a group of patients with plaque psoriasis, analyzing their gut microbiome and the relationship between the microbiome composition and bacterial translocation. The microbiome of a cohort of 52 psoriatic patients (PASI score ≥ 6) was obtained by 16s rRNA massive sequencing with MiSeq platform (Illumina inc, San Diego) with an average of 85,000 sequences per sample. The study of the gut microbiome and enterotype shows from the first time a specific “psoriatic core intestinal microbiome” that clearly differs from the one present in healthy population. In addition, those psoriatic patients classified as belonging to enterotype 2 tended to experience more frequent bacterial translocation and higher inflammatory status (71%) than patients with other enterotypes (16% for enterotype 1; and 21% for enterotype 3).

Psoriasis is considered a systemic autoimmune inflammatory and proliferative chronic disease⁹–¹¹. Although the pathogenesis of psoriasis is not well understood, it is hypothesized to be multi-factorial, influenced by genetic and immunological factors. This condition is characterized by epidermal and dermal infiltrations of activated T lymphocytes⁶. Bacterial DNA translocation (BT) in blood samples has recently been described in patients with psoriasis⁶. The results of this work suggest that new outbreaks of active plaque psoriasis may be related to the presence of circulating bacterial DNA in blood, originated from the intestinal lumen⁶. This indicates the key role played by healthy intestinal bacterial composition in reducing intestinal permeability and the risk of BT.

In recent years, in-depth studies have assessed the association between the gut microbiome and certain disorders such as cirrhosis⁷, obesity⁴, inflammatory bowel diseases⁹, diabetes¹⁰ and central neuronal disorders¹¹ among others. Recently, a study focused on autism and accompanying GI symptoms¹², found that autism patients had a distinct and less diverse gut microbial composition with lower levels of Prevotella, Caprooccus, and an unclassified Veillonellaceae. All these results suggest a potentially important role of the gut microbiome in illnesses that are not directly related to the digestive tract.

This work attempts to describe the intestinal microbial composition of psoriatic patients and the putative relation between the BT and disease worsening.

Results

A total of 52 patients previously diagnosed with plaque psoriasis by clinical, laboratory and/or histological findings were included (Supplementary Table S1). Bacterial DNA was detected in 13 blood samples (13/52 = 25%) being considered as BT-positive patients. The rest were considered as BT-negative group.

Firstly, the intestinal bacterial composition in psoriatic patients was analyzed by massive genome sequencing based on 16s rRNA, inspecting a mean of over 85,000 sequences per sample (raw and clean number of sequences,

1Lifesequencing S.L.-ADM, Catedrático Agustín Escardino Benlloch 9 Edif 2, 46980, Paterna, Valencia, Spain. 2Department of Clinical Medicine, MiBioPath group, Universidad Católica San Antonio de Murcia (UCAM), Guadalupe, Spain. 3Department of Dermatology, Hospital Universitario del Vinalopó, Elche, Spain. 4Especialidades Farmacéuticas Centrum, Alicante, Spain. 5Korott S.L., Carrer Filà Benimerines, 61, 03801, Alcoi, Alicante, Spain. 6Department of Pharmacology, Pediatrics and Organic Chemistry, Universidad Miguel Hernández de Elche, Alicante, Spain. 7Biopolis S.L.-ADM, Catedrático Agustín Escardino Benlloch 9 Edif 2, 46980, Paterna, Valencia, Spain. 8Infectious Disease Unit, Hospital Universitario del Vinalopó, Elche, Spain. Correspondence and requests for materials should be addressed to E.Ch. (email: empar.chenoll@biopolis.es)
mean length, total mega bases sequenced and mean quality per sample can be found at Supplementary Table S2 and S3 respectively) and comparing based on BT detection (Fig. 1A). The comparison did not reveal differentiated BT-positive and BT-negative populations; the latter population being nested within the former. This allowed us to describe a “psoriatic core microbiome” at genus level based on mean values of the bacteria detected in each patient as well as with the median of all patients (Supplementary Table S4). The bacterial composition of all psoriatic patients was then compared with a cohort of over 300 healthy individuals extracted from the human microbiome project (http://hmpdacc.org/). In this case, differences were observed in the intestinal bacterial composition between healthy (as considered at the Human Microbiome Project) and psoriatic groups, although some healthy people clustered closer to psoriatic patients (Fig. 1B). In general, focusing on the PCA analysis, in psoriatic patients we detected a decrease in the genus Bacteroides and an increase in Akkermansia spp. compared with the healthy group. Shannon biodiversity index was calculated (included in Supplementary Table S5) and the comparison (median, (IQ)) between healthy people and psoriatic patients rendered a significantly higher variability (p-value < 0.001) in psoriatic patients (2.94, (2.75–3.14)) compared with the healthy population (1.92, (1.27–2.41)). Moreover, we observed significant differences when comparing the diversity of BT-positive and BT-negative patients (p value = 0.013), where the variability was lower and more stable in BT-positive patients (2.83, (2.47–2.92)) than in BT-negative patients (2.99, (2.78–3.19)).

The intestinal bacterial composition was compared based on BT detection and enterotype classification (Arumugam et al.13: enterotype 1 (predominance of Bacteroides, Fig. 2A), enterotype 2 (predominance of Prevotella) (Fig. 2B) and enterotype 3 (predominance of Ruminococcus) (Fig. 2C). In no case, PCA analysis did show a strong separation between between BT+ and BT− psoriatic subjects. Regarding patients grouped in enterotype 2, we found a higher BT presence (71.4% of patients; 5/7) compared with patients classified in the other enterotypes (16.1% (5/31) for enterotype 1; p-value < 0.05 and 21.4% (3/14) for enterotype 3; p-value =< 0.076).

Further comparison of psoriatic versus healthy microbiome composition was performed (Fig. 3). The analysis showed some genera that were differentially present at psoriatic individuals, being of relevance the increase presence of Faecalibacterium and the decrease of Bacteroides. In the same sense, we compared those psoriatic patients
Figure 2. Principal Component Analysis of the microbiome composition comparing the variability of the intestinal bacteria composition of patients that undergone BT (in black) and with those that do not have bacterial translocation (in grey), differentiating between the three enterotypes, Ent1 (A), Ent2 (B) and Ent3 (C). This statistical analysis was performed using R package version 3.2.3, comparing the bacteria composition at the genera taxonomical level for each patient in order to look for groups of genera that can allow grouping samples based on the variability found. When comparing patients belonging to Ent1, PC1, or Principal Component 1, explained the 20.1% of the total variability found, and PC2 or Principal Component 2, explained the 12.0% of the total variability. Taken into account those that are associated to Ent2, PC1, or Principal Component 1, explained the 39.3% of the total variability found, and PC2 or Principal Component 2, explained the 29.4% of the total variability, where as those belonging to Ent3, PC1, or Principal Component 1, explained the 20.8% of the total variability found, and PC2 or Principal Component 2, explained the 15.7% of the total variability.
classified in any of the enterotypes with the healthy individuals classified in the same enterotype (Supplementary Figure S1) and in all cases, psoriatic patients showed an increase presence of *Faecalibacterium* and a decrease of *Bacteroides*. Analyzing differences in bacterial composition between healthy and psoriatic subjects, and among the enterotypes, although in all cases *Faecalibacterium* and *Bacteroides* changes their percentages, the highest ratio between *Faecalibacterium* and *Bacteroides* levels was observed in enterotype 2 psoriatic subjects.

Finally, we compared the microbial composition of BT+ psoriasis subjects versus healthy group, and BT− psoriasis subjects versus healthy groups (Supplementary Files 7 and 8). In the case of BT+ psoriasis subjects, genus *Streptococcus* showed 7.25 log2 Fold Change (−log10(p-value) = 20.35), but low incidence in terms of quantity in core microbiome, followed by *Bifidobacterium* (6.95 log2 Fold Change; −log10(p-value) = 6.60). Genus *Akkrermansia* showed 5.28 log2 Fold Change (−log10(p-value) = 3.39). In the case of BT− psoriasis subjects, although *Methanobrevibacter* was the genus with higher differences in log2 Fold Change (10.75 log2 Fold Change, −log10(p-value) = 11.95), its representation was scarce in final psoriatic core microbiome. Although the rest of groups remained very similar in both comparisons, genus *Clostridium* showed 6.12 log2 Fold Change in the case of BT+ versus healthy subjects (−log10(p-value) = 14.36) and 3.62 log2 Fold Change when comparing BT− versus healthy subjects (−log10(p-value) = 15.41). Differences were shown when comparing separately psoriatic BT+ and BT− core microbiome versus healthy group (Supplementary File 9). Psoriatic BT− core microbiome was very similar to the one including both BT+ and BT− subjects. In the case of BT+ versus healthy comparison, *Parabacteroides*, *Collinsella*, *Blautia* and *Ruminococcus* groups were not differentially present.

**Discussion and Conclusions**

In order to evaluate the differences in psoriatic gut microbiome and its relation with BT, the microbiome of a cohort of 52 psoriatic patients has been analyzed in this work. The results of this preliminary analysis show a defined microbial structure in patients with psoriasis, and that this "psoriasis microbiome" clearly differs from the healthy population. Moreover, the relation between this microbial composition and bacterial translocation (BT) from the intestinal lumen is shown.

Compared with healthy data, the psoriatic microbiome was shown more diverse than healthy population. In a study conducted with 15 patients with skin psoriasis, Scher et al. found a decreased in bacterial diversity when compared to that in healthy controls. These differences could be explained by different factors: i) in our study, psoriatic severity was higher (PASI mean 6.3 in Scher et al. vs. 13.3 in our study), and that could imply differences in gut microbiome, and ii) differences in massive sequencing platform and sequenced region (V1-V2 in Scher et al. vs. V3-V4 in our study). The psoriatic microbiome obtained in our study was defined by an increase presence of *Faecalibacterium* and a decrease of *Bacteroides*. The genera *Akkrermansia* and *Ruminococcus* showed higher values in psoriatic patients, on the contrary to Scher et al.14 findings, that found lower levels of both groups in psoriatic and arthritis psoriatic patients. *Faecalibacterium* species has been shown at levels of around 5% from the gut bacterial population19 and remarkably its increase in gut microbiota has been associated with immune-regulation. Previous works have analyzed the role of *Faecalibacterium* (*F. prausnitzii*) in inflammation, with a negative correlation between the abundance of this group and irritable bowel syndrome and celiac disease, among others16. Other researchers have found that an increase in species belonging to this genus is associated with inflammation diseases such Chron disease17. Regarding skin-associated diseases, a dysbiosis in *Faecalibacterium* subspecies have been shown to have enriched percentages in infants with eczema18 and an impact on gut epithelial barrier and as a result on atopic dermatitis19. In this study, Shong et al. found compositional changes in *Faecalibacterium prausnitzii* in atopic dermatitis patients, always with increased levels at the genera level in these patients compared with non-atopic dermatitis patients (following our findings in psoriasis), but with an impact lowering high butyrate and propionate *Faecalibacterium* strain producers. Butyrate and propionate are short chain fatty...
aggressive treatment. Therefore, the detection of BT could play a crucial role in a patient’s response to treatment.

Parabacteroides, Collinella, Blautia and Ruminococcus groups were differentially present only in BT− subjects but, considering that BT+ represented only 25% of psoriatic people included in the study, these differences must be considered as a punctual result, and further studies should be applied to confirm. Analyzing differences within different enterotypes, our results suggest that psoriatic patients with a relevant presence of Prevotella in the intestinal microbiome (enterotype 2) and lower ratio Bacteroides/ Faecalibacterium, can be more prone to BT.

All these results suggest that bacterial translocation in psoriasis is not induced by one specific microbial group; the event probably is caused by a microbial imbalance among different groups in gut, which may alter organic acid compounds and other molecules, acquiring an inflammation state which leads to bacterial translocation events, among others. Although in our study PASI scores were similar between BT+ and BT− subjects (BT+, PASI average 12.51 ± 4.19; BT−, PASI average 12.77 ± 4.64), it has been previously reported that BT boosts the pro-inflammatory response, promoting skin inflammation, and consequently these patients may require a more aggressive treatment. Therefore, the detection of BT could play a crucial role in a patient’s response to treatment.

If we take into account that patients classified in enterotype 2 have a greater likelihood of bacterial DNA being present in blood, an inspection of the bacteria present in stools could be used as one of the follow-up indicators in psoriatic patients, to detect BT events and a stronger inflammatory response.

All in all, the knowledge here communicated, holds conceivable promise for developing novel prognosis and most efficient therapeutics avenues, including antibiotics, probiotics and prebiotics for psoriasis treatment.

Methods

Study population. The patients evaluated for inclusion in this study had previously been diagnosed with plaque psoriasis by clinical, laboratory and/or histological findings; they had a PASI score ≥6 and they attended a dermatological clinic from September 2014 to December 2014. A peripheral blood sample was collected from all participants and analyzed for routine biochemical laboratory values, as well as for interleukin (IL) 1β, IL-6, IL-12, IL-23, tumor necrosis factor, and interferon-γ levels. An aliquot of blood was inoculated under aseptic conditions in sterile, rubber-sealed Vacutainer SST II tubes (BD Diagnostics) to detect and identify the origin of bacterial DNA fragments in blood. Finally a stool sample was obtained from all patients and immediately frozen and stored at −80°C until their processing for massive genome sequencing. Exclusion criteria were the following: the use of immunosuppressant drugs such as systemic corticosteroids, methotrexate, cyclosporine or anti-tumor necrosis factor alpha (TNFs) drugs in the previous 3 months, systemic antibiotics in the previous 2 weeks, and the concomitant diagnosis of cirrhosis, intestinal bowel disease and signs of bacterial infection.

The study was run in accordance with the Helsinki Declaration, as amended in successive world assemblies. The protocol received approval from the Ethics Committee for Clinical Research (CEIC) of the Hospital General Universitario de Alicante, and the “Agencia Española del Medicamento” (Spanish Medicines Agency). All patients gave their written informed consent before their inclusion in the study. There was no change to the trial protocol after it commenced. All methods were performed in accordance with the relevant guidelines and regulations.

Bacterial DNA identification in peripheral blood. To detect and identify the origin of bacterial DNA fragments in blood, we performed a broad-range polymerase chain reaction and nucleotide sequencing analysis according to the methodology previously described

Briefly, DNA was isolated with QIAmp DNA Blood Mini Kit (QIAgen, Hilden, Germany) and a broad-range PCR amplification of the bacterial 16s rRNA gene conserved region was performed using the following primers: 5′-TTCCGGTTGATCCTGCCGGA-3′ as forward, and 5′-GGTTACCCTTGGTACGACTT-3′ as reverse. Bacterial DNA fragments were purified with QIAquick purification kit (QIAgen) and purified amplicons were used for the sequencing reactions with Big Dye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA, US). The same reverse oligonucleotide for PCR amplification was used as a sequencing primer. The final product was analyzed in the ABI PRISM 310 automated sequencer (Applied Biosystems). Sequences obtained were compared with the database from the National Center for Biotechnology Information (NCBI, www.ncbi.nlm.nih.gov) using the advanced BLAST search tool.

Massive genome sequencing of stool samples of patients with psoriasis. DNA from stool samples was isolated following Yuan and coworkers with minor modifications, with the aid of MagnaPure Compact System (Roche Life Science), to avoid bias in DNA purification toward misrepresentation of gram-positive bacteria. For massive sequencing, the hypervariable region V3-V4 of the bacterial 16s rRNA gene was amplified using key-tagged eubacterial primers and sequenced with a MiSeq Illumina Platform, following the Illumina recommendations for Library preparation and sequencing for metagenomics studies. The bacterial composition of all patients was compared with a cohort of healthy sex- and age-matched individuals extracted from the human microbiome project (http://hmpdacc.org/).

Bioinformatics. The resulting sequences were split taking into account the barcode introduced during the PCR reaction, while R1 and R2 reads were overlapped using PEAR program version 0.9.125 providing a single FASTQ file for each of the samples. Quality control of the sequences was performed in different steps, (i) quality
filtering (with a minimum threshold of Q20) was performed using fastx tool kit version 0.0.13, (ii) primer (16S rRNA primers) trimming and length selection (reads over 300 nts) was done with cutadapt version 1.4.129. These FASTQ files were converted to FASTA files and UCHIME program version 7.0.1001 was used in order to remove chimeras that could arise during the amplification and sequencing steps. Those clean FASTA files were BLAST27 against NCBI 16S rRNA database using blastn version 2.2.29+. The resulting XML files were processed using a python script developed by Lifesequencing S.L.- ADM (Paterna, Valencia, Spain) in order to annotate each sequence at different phylogenetic levels (Phylum, Family, Genus and Species).

**Statistical Analysis.** Descriptive quantitative variables were expressed as means ± SD and as frequencies for qualitative variables. Comparisons between groups were performed with U Mann-Whitney test for quantitative data, while qualitative variables were analyzed using the chi-square and Fisher tests. The odds ratio (OR) with a 95% confidence interval (CI) was taken as a measure of effect size. A 2-tailed p value of less than 0.05 was considered to indicate statistical significance. All statistical analyses (PCA) were performed using IBM SPSS statistics version 22. (SPSS Inc. Chicago, IL) and R version 3.2.3. In the case of microbiome analysis, alpha diversity was conducted using specaccum program in the vegan package28 as implemented for R version 3.2.3. R Packages ggplot229, DESeq2 30 and ggbiplot31 were used for the analysis. Diversity was analyzed by using QIIME microbiome pipeline32.

**Availability of data and material.** The datasets supporting the conclusions of this article are included and available on line. Raw fastq data will be available upon request to the corresponding author.

**References**

1. Haroon, M., Gallagher, P., Heffernan, E. & Fitzgerald, O. High prevalence of metabolic syndrome and insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. *J. Rheumatol.* **41**, 1357–1365 (2014).
2. Mrowietz, U. et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. *Arch. Dermatol. Res.* **303**, 1–10 (2011).
3. Deng, Y., Chang, C. & Lu, Q. The inflammatory response in psoriasis: a comprehensive review. *Clin. Rev. Allergy Immunol.* **50**, 377–389 (2016).
4. Such, J. Regulation of Inflammation by Short Chain Fatty Acids.
5. Schäfer, T. Epidemiology of psoriasis. Review and the German perspective.
6. Mallbris, L. Psoriasis phenotype at disease onset: clinical characterization of 400 adult cases. *J. Invest. Dermatol.* **124**, 499–504 (2005).
7. Scher, J. U. Microbial butyrate and its role for barrier function in the gastrointestinal tract.
8. Scher, J. U. Decreased Bacterial Diversity Characterizes the Altered Gut Microbiota in Patients With Psoriatic Arthritis, Resembling Dysbiosis in Inflammatory Bowel Disease. *Arthritis Rheum.* **67**, 128–139 (2015).
9. Miquel, S. et al. Faeceibacterium prausnitzii and human intestinal health. *Current Opinion in Microbiology* **16**, 255–261 (2013).
10. Hansen, R. et al. Microbiota of de-novo pediatric IBD: increased Faecibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. *Am J Gastroenterol.* **107**, 1913–1922, https://doi.org/10.1038/ajg.2012.335 (2012).
11. Zheng, H. Impaired gut microbiota composition associated with eczema in infants. *PLoS ONE* **11**, e0166026, https://doi.org/10.1371/journal.pone.0166026 (2016).
12. Song, H., Yoo, Y., Hwang, J., Na, Y.-C. & Kim, H. S. Faecibacterium prausnitzii subspecies–level dysbiosis in the human gut microbiome underlying atopic dermatitis. *J. Allergy Clin. Immunol.* **157**, 852–860 (2016).
13. Vinolo, M. A. R., Rodrigues, H. G., Nachbar, R. T. & Curi, R. Definition of treatment goals for moderate to severe psoriasis: a European consensus.
14. DeGruttola, A. K., Low, D., Mizoguchi, A. & Mizoguchi, E. Current understanding of dysbiosis in disease in human and animal models. *Inflamm. Bowel Dis.* **22**, 1137–1150 (2016).
15. Foster, J. A. & McVey Neufeld, K. A. Gut-brain axis: how the microbiome influences anxiety and depression. *Trends Neurosci.* **36**, 305–312 (2013).
16. Kang, D.-W. et al. Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. *PLoS ONE* **8**, e68322, https://doi.org/10.1371/journal.pone.0068322 (2013).
17. Ahluwalia, V. et al. Impaired gut-liver-brain axis in patients with cirrhosis. *Sci. Rep.* **6**, 26890 (2016).
18. Angielakis, E., Armsgoum, E., Million, M. & Raoul, D. The relationship between gut microbiota and weight gain in humans. *Future Microbiol.* **7**, 91–109 (2012).
19. DeGruttola, A. K., Low, D., Mizoguchi, A. & Mizoguchi, E. Current understanding of dysbiosis in disease in human and animal models. *Inflamm. Bowel Dis.* **22**, 1137–1150 (2016).
20. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet.journal.* **17**, 10–12 (2011).
21. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. *J. Mol. Biol.* **215**, 403–410 (1990).
22. Oksanen, J. et al. vegan: Community Ecology Package. R package version 2.4-3. https://CRAN.R-project.org/package=vegan (2017).
23. Bioinformatics. *Nature Methods* **7**, 335–336 (2010).
24. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet.journal.* **17**, 10–12 (2011).
25. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. *J. Mol. Biol.* **215**, 403–410 (1990).
26. Oksanen, J. et al. Community Ecology Package. R package version 2.4-3. https://CRAN.R-project.org/package=vegan (2017).
27. H. Wickham. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York, 2009.
28. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
29. Vu, V. Q. ggbiplot: A ggplot2 based biplot. R package version 0.55, http://github.com/vqv/ggbiplot (2011).
30. Caperaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods* **7**, 335–336 (2010).
31. Ramírez-Boscá, A. et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. *Gut* **65**, 426–436 (2016).
32. Dominguez-Bello, M. G. et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. *Hepatology.* **57**, 1357–1365 (2013).
33. Ahlswede, V. et al. Impaired gut-liver-brain axis in patients with cirrhosis. *Sci. Rep.* **6**, 26890 (2016).
34. Angielakis, E., Armsgoum, E., Million, M. & Raoul, D. The relationship between gut microbiota and weight gain in humans. *Future Microbiol.* **7**, 91–109 (2012).
35. DeGruttola, A. K., Low, D., Mizoguchi, A. & Mizoguchi, E. Current understanding of dysbiosis in disease in human and animal models. *Inflamm. Bowel Dis.* **22**, 1137–1150 (2016).
36. DeGruttola, A. K., Low, D., Mizoguchi, A. & Mizoguchi, E. Current understanding of dysbiosis in disease in human and animal models. *Inflamm. Bowel Dis.* **22**, 1137–1150 (2016).
37. Ahluwalia, V. et al. Impaired gut-liver-brain axis in patients with cirrhosis. *Sci. Rep.* **6**, 26890 (2016).
38. Angielakis, E., Armsgoum, E., Million, M. & Raoul, D. The relationship between gut microbiota and weight gain in humans. *Future Microbiol.* **7**, 91–109 (2012).
39. DeGruttola, A. K., Low, D., Mizoguchi, A. & Mizoguchi, E. Current understanding of dysbiosis in disease in human and animal models. *Inflamm. Bowel Dis.* **22**, 1137–1150 (2016).
40. DeGruttola, A. K., Low, D., Mizoguchi, A. & Mizoguchi, E. Current understanding of dysbiosis in disease in human and animal models. *Inflamm. Bowel Dis.* **22**, 1137–1150 (2016).
41. DeGruttola, A. K., Low, D., Mizoguchi, A. & Mizoguchi, E. Current understanding of dysbiosis in disease in human and animal models. *Inflamm. Bowel Dis.* **22**, 1137–1150 (2016).
42. DeGruttola, A. K., Low, D., Mizoguchi, A. & Mizoguchi, E. Current understanding of dysbiosis in disease in human and animal models. *Inflamm. Bowel Dis.* **22**, 1137–1150 (2016).
43. DeGruttola, A. K., Low, D., Mizoguchi, A. & Mizoguchi, E. Current understanding of dysbiosis in disease in human and animal models. *Inflamm. Bowel Dis.* **22**, 1137–1150 (2016).
Acknowledgements
We thank Encarna Espejo, Leticia Sánchez, and Gabriel Caravaca for their support in the field of laboratory; Vicente García and Humberto Gómez for their support in the field of statistics and Beatriz Ruzafa and Alfonso del Pozo for their technical and computing support. We also thank to Ángela Silva from Biopolis S.L.-ADM and Juan Fco Martinez, Juan Ureña, M. Carmen Solaz and Laura Llobregat from Lifesequencing S.L.-ADM for their laboratory technical support.

Author Contributions
V.N.L., A.R.B., S.G., E.C., J.H.P. and D.R. equally contributed to experimental design and analysis. F.C., E.C., M.C.-G., M.G. and E.C.L. performed, analyzed and generated the experiments shown in Figs 1–3, which data were validated by S.G., J.M.M.-P. and M.G. F.C., V.N.L. and E.C. wrote the manuscript. All authors reviewed the manuscript. All authors contributed to the interpretation of findings and edition of the final manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-22125-y.

Competing Interests: D.R., S.G. and E.C. are employees of Biopolis, S.L.-ADM. F.C., E.C.L. and D.R. are employees of Lifesequencing, S.L.-ADM. M.G. is an employee of Especialidades Farmacéuticas Centrum. J.M.P.-O. is an employee of Korott. V.N.L., A.R.B., J.H.P and M.G. state no conflict of interest.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018